/PRNewswire/ ABILITY DIABETES-GLOBAL (ADG), is the World s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing.
Get latest articles and stories on Business at LatestLY. ABILITY DIABETES-GLOBAL (ADG), is the World s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting stent, Abluminus DES+ (Concept Medical Inc.) with the XIENCE family of DES (Abbott Cardiovascular). Business News | ABILITY DIABETES GLOBAL - A Landmark RCT in the Field of PCI for Patients with DM, Completes Enrolment.
The powerful LDL-lowering agents aren t being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.
Although interest in renal denervation in hypertension fell off after disappointing results from the 2014 trial, a new, longer-term analysis argues the treatment may have worked after all.